Established to support Canadian Oncology Research
- Ozmosis is a Canadian social enterprise CRO investing profits into research
- Spin out of Drug Development Program from Princess Margaret Cancer Centre
Our Executive Team
Our Executive Team has extensive experience designing and managing oncology clinical trials
Board of Directors
Our Board comprises a collection of world leaders in oncology research and provides leadership and scientific expertise
Dr Amit Oza is a Senior Staff Physician and Professor of Medicine at Princess Margaret Cancer Centre, University of Toronto. He is a Scientist with the Ontario Cancer Institute and cross-appointed to the Department of Obstetrics and Gynecology at the University of Toronto. He graduated from St. Bartholomew’s Hospital, University of London (UK), in 1983 and completed his internal medicine and medical oncology training in the UK. He completed Clinical Research Fellowships at St. Bartholomew’s Hospital/Imperial Cancer Research Fund, London (UK), Princess Margaret Cancer Centre, Toronto and at the Netherlands Cancer Institute, Amsterdam. His postgraduate research thesis was on Molecular Epidemiology of Hodgkin’s Disease. He is a Fellow of the Royal College of Physicians of London and Canada.
Dr Oza has been the principal investigator and co-investigator in phase I, II, and III trials for gynaecological cancer and advanced colorectal malignancies. His research interests are focused on the development, assessment, and validation of novel therapeutic strategies for cancer including molecular targeted therapies. Many of these studies also incorporate novel endpoints and translational research which is developed in close relationship with scientists and pathologists from the OCI/PMCC.
Dr Oza has been the recipient of various awards such as the University of Toronto Award for Teaching Excellence for the Medical Oncology Training Program, the Hasselback Award for Teaching Excellence from Princess Margaret Hospital and many others. He has also been principal and co-author of numerous publications in major peer-reviewed journals such as Cancer Research, Journal of Clinical Oncology, Annals of Oncology, Investigational New Drugs and Clinical Cancer Research.
He is currently Medical Director of the Clinical Cancer Research Unit at Princess Margaret Cancer Centre and Co-Director of the Robert and Maggie Bras and Family Drug Development Program at Princess Margaret Cancer Centre. This is the largest new drug development program in Canada and the only centre outside the US to have a contract with the NIH for Early Phase Therapeutic studies. He is also Co-Chair of the Gynecology Site Committee of the NCIC Clinical Trials Group and represents NCIC CTG at the Gynecologic Cancer InterGroup.
Dr. Jeffrey Coull is an entrepreneur and neuroscientist. Presently, he serves as Head of Strategic Initiatives at the Weston Family Foundation (which encompasses the Weston Brain Institute) and is advising Sunnybrook Research Institute on the development of a revolutionary medical device for treating disorders of the central nervous system.
Previously, Jeff built and ran two venture-backed biotech companies (Chlorion Pharma and Encycle Therapeutics); Encycle Therapeutics was acquired by Zealand Pharma in 2019. He also participated in the establishment of the Ontario Brain Institute and served as an Adjunct Professor at the University of Toronto for several years.
Jeff holds a PhD from McGill University, where he undertook neuroscience research. Elements of his research findings were published in Nature and formed the basis for several patent applications. In addition, his dissertation was recognized by the Natural Sciences and Engineering Research Council with a Doctoral Prize, the highest distinction for PhD research in Canada.
Concurrently with his undergraduate education at Queen’s University, Jeff served in the reserve of the Royal Canadian Navy.
Jeff is an avid squash player and skier and resides in Toronto with his wife and three children.
Arjeta Meneri is Senior Legal Counsel at the University Health Network (“UHN”), where she provides corporate and health law legal services to hospital executive leadership, medical professional leadership and hospital departments across all hospital sites of UHN. She received her B.Sc. in Anatomy and Cell Biology at McGill University and obtained her Juris Doctor degree at the University of Toronto, Faculty of Law.
Prior to joining UHN, she was an Intellectual Property associate lawyer at Norton Rose Fulbright Canada LLP, where she represented pharmaceutical companies before the Federal Court of Canada. At UHN she has previously held the position of Manager and Legal Counsel of the Clinical Trial Agreements Office, where she oversaw and managed the clinical research legal portfolio of UHN and provided advice to research executives, research leadership and the clinical research community. Arjeta is a graduate of the Rotman Executive “Business Leadership Program for In-House Counsel” and a Certified In-House Counsel with the Canadian Corporate Counsel Association.
Dr. Christine Williams is an immunologist and currently serves as the Deputy Director at the Ontario Institute for Cancer Research (OICR).
As part of OICR’s executive team, Dr. Williams works with the Institute’s scientists, senior leaders and partners to develop and implement strategic priorities across the Institute’s translational research programs. She leads coordinated engagement and communications strategies, oversees research operations and stewards OICR research assets through commercialization and into the health system to advance OICR’s mission. Dr. Williams focuses on developing and maintaining OICR’s collaborative relationships with a broad range of provincial, national and international stakeholders including clinical, academic, industry, government and patient partners.
Dr. Williams received an undergraduate degree in Life Sciences from Queen’s University and a PhD in Immunology from the University of Toronto. She received postdoctoral training at Massachusetts General Hospital and Harvard University where she studied the molecular pathways involved in the development of leukemia and lymphoma in children. Prior to her role at OICR, Dr. Williams held various leadership positions at the Canadian Cancer Society, most recently as its Chief Mission Officer & Scientific Director, responsible for strategy development and program delivery nationwide.
Dr. Williams is currently a member of boards and advisory committees for a number of organizations, including the Canadian Cancer Research Alliance, the Canadian Institutes of Health Research, CanPath, The Canadian Cancer Clinical Trials Group and BioCanRx.
Our Value Proposition
Solid tumour, malignant hematology, and clinical trial design
Knowledgeable and committed team working collaboratively with sponsors to successfully operationalize and execute their trials
Strong relationships with sites across North America, Europe, and Australia
A flexible and adaptable organization that can help to expedite trial initiation and patient recruitment